Related Experiment Video
Updated: Dec 21, 2025
Anteromesial Temporal Lobectomy for Medically Intractable Temporal Lobe Epilepsy: An Operative Study
Published on: August 15, 2025
Stereotactic Laser Ablation for Mesial Temporal Lobe Epilepsy: A prospective, multicenter, single-arm study
Michael R Sperling1, Robert E Gross2, Guy E Alvarez3
1Thomas Jefferson University, Philadelphia, PA, USA.
Objective:
To describe the development of the Stereotactic Laser Ablation for Temporal Lobe Epilepsy study protocol in the context of current practice. An ideal treatment for drug-resistant epilepsy remains an ongoing area of research. Although there are several options available, each has challenges that not only make deciding on the appropriate treatment not clear-cut but also create difficulties in designing clinical studies to provide evidence in support of the treatment.
Methods:
A prospective, single-arm, multicenter study designed to evaluate safety and efficacy of the VisualaseTM MRI-Guided Laser Ablation System for the treatment of temporal lobe epilepsy will include up to 150 patients with a primary efficacy endpoint of seizure freedom (defined as Engel Class I) for the first 12 months following the procedure and a primary safety endpoint of incidence of qualifying device-, procedure-, or anesthesia-related adverse events through 12 months following the procedure.
Results:
Primary endpoints will be assessed against historical values of safety and efficacy of anterior temporal lobectomy.
Significance:
The scientific and payor communities typically demand randomized controlled trials (RCTs) as definitive evidence for safety and efficacy claims. However, in circumstances where the medical device has already been cleared by regulatory authorities and is readily available in the market, an RCT may not be feasible to execute. It is therefore crucial to gain acceptance by both the scientific community and regulators to design a study that will satisfy all concerned.
Insights
This study protocol outlines a new approach for drug-resistant epilepsy using stereotactic laser ablation. The Visualase system will be evaluated for safety and efficacy in treating temporal lobe epilepsy patients.
Area of Science:
- Neurology
- Neurosurgery
- Medical Device Technology
Background:
- Drug-resistant epilepsy presents ongoing treatment challenges.
- Current treatment options have limitations, complicating clinical study design.
- There is a need for robust evidence supporting novel epilepsy therapies.
Purpose of the Study:
- To describe the development of the Stereotactic Laser Ablation for Temporal Lobe Epilepsy (SLATE) study protocol.
- To evaluate the safety and efficacy of the Visualase MRI-Guided Laser Ablation System for temporal lobe epilepsy.
- To establish a study design that satisfies scientific and regulatory requirements for a cleared medical device.
Main Methods:
- Prospective, single-arm, multicenter study.
- Enrollment of up to 150 patients with temporal lobe epilepsy.
- Primary endpoints: seizure freedom (Engel Class I) at 12 months and safety of device-, procedure-, or anesthesia-related adverse events.
Main Results:
- Primary efficacy endpoint: seizure freedom at 12 months post-procedure.
- Primary safety endpoint: incidence of adverse events within 12 months.
- Endpoints will be compared against historical data from anterior temporal lobectomy.
Conclusions:
- The SLATE study protocol aims to provide evidence for stereotactic laser ablation in drug-resistant epilepsy.
- The study design addresses the challenges of evaluating a cleared medical device.
- This approach seeks acceptance from scientific and regulatory bodies for novel epilepsy treatments.
